Bausch Health Companies (BHC)

A major part of Bausch Health’s portfolio is Salix, its U.S. gastrointestinal medicines business, which markets treatments used in areas such as irritable bowel syndrome with diarrhea, hepatic encephalopathy, and other digestive conditions. The company also sells a range of dermatology and diversified pharmaceutical products, while Solta Medical provides aesthetic medical devices used by physicians for skin resurfacing, body contouring, and related procedures.

Bausch Health is also closely associated with Bausch + Lomb, one of the best-known names in vision care. Bausch + Lomb’s activities include contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical equipment used in eye procedures. This eye health platform has historically represented the largest source of revenue in Bausch Health’s reporting structure.

For investors, BHC represents exposure to a healthcare company with a broad mix of prescription drugs, consumer brands, and device-based businesses. Its performance is influenced by product demand, patent and generic competition, regulatory developments, physician adoption, international sales trends, and the company’s ongoing efforts to manage its portfolio and balance sheet.